Breaking News, Trials & Filings

AbbVie’s ELAHERE Granted Marketing Authorization in EU for Ovarian Cancer

The marketing authorization is supported by data from MIRASOL, a global, Phase 3 open-label, randomized, controlled trial.

Author Image

By: Charlie Sternberg

Associate Editor

The European Commission (EC) has granted marketing authorization for AbbVie’s ELAHERE (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.   ELAHERE is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine approved in the European Union...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters